MYELOMATCH, "Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials"

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have.

For more information, please visit: https://clinicaltrials.gov/study/NCT05564390?id=NCT05564390&rank=1#contacts-and-locations

Inova Schar Cancer 
8081 Innovation Park Drive, Fairfax 22031

Inova Fairfax Medical Campus
3300 Gallows Rd,
Falls Church, VA 22042
571-472-4724 (24 hour)

• Participants must be suspected to have previously untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). For participants assigned an AML basket protocol, there cannot be a history of previous myeloproliferative neoplasm (MPN) or MDS.
• Participants must be >= 18 years of age.
• Participants must agree to have specimens submitted. Note: Email notification of treatment protocol assignment must be received prior to treatment protocol registration.
• Participants must be offered the opportunity to participate in specimen banking. Note: With participant consent, specimens must be collected and submitted via the Clinical/Correlative Sample Management System (CSMS).
• Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.

• Participants must not have received prior anti-cancer therapy for AML or MDS.
  • Note: Hydroxyurea to control the white blood cell count (WBC) is allowed.
• Participants must not have a prior or concurrent malignancy that requires concurrent anti-cancer therapy
  • Note: active hormonal therapy is allowed